<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721600</url>
  </required_header>
  <id_info>
    <org_study_id>DO609576A</org_study_id>
    <nct_id>NCT04721600</nct_id>
  </id_info>
  <brief_title>Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance</brief_title>
  <official_title>Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the safety, efficacy, patient comfort, and patient&#xD;
      satisfaction after Evoke treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate change in skin appearance</measure>
    <time_frame>Day 0, Month 6</time_frame>
    <description>Evaluate change in skin appearance comparing pre 6 months post last treatment photographs (as assessed by blinded investigators)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Improvement in skin appearance</measure>
    <time_frame>Day 0, month 6</time_frame>
    <description>Evaluate Improvement in skin appearance using 3D Photographic analysis at 6 months follow up visits and compared to the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator assessment of the skin appearance</measure>
    <time_frame>month 6</time_frame>
    <description>Evaluate Investigator assessment of the skin appearance comparing pre and post-treatment using 0 - 4 -points Likert scale at 6 months follow up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of change and satisfaction</measure>
    <time_frame>month 6</time_frame>
    <description>Evaluate Subject assessment of change and satisfaction using 0 - 4 -points Likert scale at 6 months follow up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Analysis - Quantitative analysis of collagen fibers (up to 5 subjects)</measure>
    <time_frame>Day 0, month 3</time_frame>
    <description>Quantitative analysis of collagen will be performed with the Image software by semi-automatic segmentation in HSB (Hue-Saturation-Brightness) color system. The change from baseline will be calculated at 3 months time frame.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Skin Laxity</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evoke Radiofrequency Device</intervention_name>
    <description>Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Signed informed consent to participate in the study.&#xD;
&#xD;
          -  Female and male subjects, 35 and 75 years of age at the time of enrolment&#xD;
&#xD;
          -  If female, not pregnant, lactating and must be either post-menopausal, surgically&#xD;
             sterilized, or using a medically acceptable form of birth control at least 3 months&#xD;
             prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods&#xD;
             with spermicide or abstinence).&#xD;
&#xD;
          -  In addition, negative urine pregnancy test as tested before each treatment and at the&#xD;
             last visit for women with childbearing potential (e.g. not menopause).&#xD;
&#xD;
          -  General good health confirmed by medical history and skin examination of the treated&#xD;
             area.&#xD;
&#xD;
          -  Willing to have photographs and images taken of the treated areas to be used&#xD;
             de-identified in evaluations, publications and presentations.&#xD;
&#xD;
          -  The patients should be willing to comply with the study procedure and schedule,&#xD;
             including the follow up visit, and will refrain from using any other aesthetic&#xD;
             treatment methods for the last 6 months and during the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pacemaker or internal defibrillator, or any other active electrical implant anywhere&#xD;
             in the body.&#xD;
&#xD;
          -  Permanent implant in the treated area such as metal plates and screws, silicone&#xD;
             implants or an injected chemical substance, unless deep enough in the periostal plane.&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or premalignant moles.&#xD;
&#xD;
          -  Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled&#xD;
             hypertension, and liver or kidney diseases.&#xD;
&#xD;
          -  Pregnancy and nursing.&#xD;
&#xD;
          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use&#xD;
             of immunosuppressive medications.&#xD;
&#xD;
          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and&#xD;
             rash.&#xD;
&#xD;
          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin.&#xD;
&#xD;
          -  History of bleeding coagulopathies or use of anticoagulants in the last 10 days.&#xD;
&#xD;
          -  Any surgery in treated area within 3 months prior to treatment.&#xD;
&#xD;
          -  Six months delay is required if other recent treatments like light, CO2 laser or RF&#xD;
             were performed on the same area.&#xD;
&#xD;
          -  Use of Isotretinoin (AccutaneÂ®) within 6 months prior to treatment.&#xD;
&#xD;
          -  As per the practitioner's discretion, refrain from treating any condition that might&#xD;
             make it unsafe for the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Dover, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skincare physicians</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Shusterman</last_name>
    <phone>905-707-6787</phone>
    <email>maria.shusterman@inmodemd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leon Grach</last_name>
    <phone>905-707-6787</phone>
    <email>Leon.Grach@inmodemd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skincare physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Petrell</last_name>
      <phone>617-848-1638</phone>
      <email>kpetrell@skincarephysicians.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Dover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

